Watch Jubilant Life Sciences on acquisition front

Jubilant Life Sciences’ subsidiary Jubilant Pharma (JPL) is going to acquire Triad Isotopes Inc. The company will acquire substantially all assets which comprise the radiopharmacy business of Triad. Its share price will be watched out on Friday, it has closed at Rs 734.4 with a gain of 0.1 per cent on Thursday.

The acquisition is a strategic fit to Jubilant’s niche nuclear medicine business and will provide the company with direct access to hospital networks with the ability to deliver more than 3 million patient doses annually through approximately 1700 customers. It will also facilitate forward integrate into the radiopharmaceutical business, which in turn help directly to serve healthcare providers and their patients with high-quality radiopharmaceutical products.

Jubilant Life Sciences will utilise internal accruals for proposed acquisition. The so-called acquisition will give earnings accretive in the first full year of operations.

On the financial front, Triad recorded revenue of USD 225 million (Rs 64.24 crore) in CY2016. The company operates the second largest radiopharmacy network in the US with more than 50 pharmacies, distributing nuclear medicine products to the largest National GPOs, regional health systems, stand-alone imaging centres, cardiologists and hospitals.